Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Abstract

Among patients with newly diagnosed advanced ovarian cancer who had a response to platinum-based chemotherapy, those who received niraparib had significantly longer progression-free survival than those who received placebo, regardless of the presence or absence of homologous-recombination deficiency. (Funded by GlaxoSmithKline; PRIMA/ENGOT-OV26/GOG-3012 ClinicalTrials.gov number, NCT02655016.).

Keywords

Affiliated Institutions

• KU Leuven BE
• Universitat de Girona ES
• University of Southern Denmark DK
• Copenhagen University Hospital DK
• Hôpital Lyon Sud FR
• Fondazione IRCCS Istituto Nazionale dei Tumori IT
• Creighton University US
• University of Rochester US
• Technion – Israel Institute of Technology IL
• Klinikum Ludwigshafen DE
• McGill University Health Centre CA
• Tesaro (United States) US
• Hillel Yaffe Medical Center IL
• Biomedical Research Institute US
• University of Pennsylvania US
• Institut Català d'Oncologia ES
• GlaxoSmithKline (United States) US
• Rigshospitalet DK
• Hospital Universitario Reina Sofía ES
• Thomas Jefferson University US
• University of Antwerp BE
• University of Arizona US
• Hospital Universitario La Paz ES
• Medical College of Wisconsin US
• Vita-Salute San Raffaele University IT
• Aalborg University DK
• NYU Langone Health US
• The Ohio State University US
• McGill University CA
• Cancer Institute (WIA) IN
• AZ Maria Middelares BE
• Cornell University US
• Clinica Universidad de Navarra ES
• Medical University of South Carolina US
• Memorial Sloan Kettering Cancer Center US
• Jefferson Hospital US
• Spanish Ovarian Cancer Research Group ES
• Gynecologic Oncology Group US

Related Publications